Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:tocilizumab
|
| gptkbp:affects |
lungs
|
| gptkbp:associated_with |
gptkb:hospital
gptkb:Company mental health issues hypertension international travel obesity public gatherings neurological conditions smoking economic impact healthcare settings COVID-19 variants chronic lung disease poor air quality renal disease immunocompromised status community transmission super-spreader events |
| gptkbp:caused_by |
gptkb:SARS-Co_V-2
|
| gptkbp:complications |
sepsis
lung fibrosis acute respiratory distress syndrome (ARDS) |
| gptkbp:end_of_life |
varies by age group
higher in patients with comorbidities |
| gptkbp:healthcare |
lockdowns
travel restrictions testing and contact tracing |
| https://www.w3.org/2000/01/rdf-schema#label |
COVID-19 pneumonia
|
| gptkbp:is_protected_by |
vaccination
mask wearing social distancing |
| gptkbp:propagation_method |
airborne droplets
|
| gptkbp:research_focus |
treatment protocols
vaccine efficacy long COVID |
| gptkbp:risk_factor |
underlying health conditions
older age |
| gptkbp:social_responsibility |
CT scan
chest X-ray variant strains PCR test high transmission rate global pandemic |
| gptkbp:symptoms |
gptkb:COVID-19
fatigue cough fever chest pain shortness of breath |
| gptkbp:treatment |
monoclonal antibodies
corticosteroids oxygen therapy antiviral medications |